New Nordic Healthbrands (NNH) Q2 2025 earnings summary

Executive summary

• Net sales increased by 1.5% in SEK (7.6% in local currencies) to SEK 143.0 million in Q2 2025 compared to Q2 2024; first half sales up 5.8% in SEK (9.0% in local currencies) to SEK 286.8 million year-over-year.

• Operating profit improved to SEK 3.8 million in Q2 2025 from -SEK 1.9 million; net profit after tax rose to SEK 2.1 million from -SEK 4.5 million.

• Cash flow from operating activities was SEK 3.5 million in Q2 2025, up from SEK 0 million; for the first half, it improved to -SEK 2.8 million from -SEK 15.8 million.

• Growth was driven by strong sales of new product innovations, with Europe and Central Asia showing double-digit growth, while the Nordics and Rest of World saw declines.

Financial highlights

• Gross margin in Q2 2025 was 64.8% (down from 65.4%); gross profit reached SEK 92.6 million (up from SEK 92.1 million).

• EBITDA for Q2 2025 was SEK 4.4 million, up from -SEK 1.4 million; for the first half, SEK 9.9 million versus -SEK 4.7 million year-over-year.

• Earnings per share in Q2 2025 were SEK 0.34 (up from -SEK 0.72); for the first half, SEK 0.77 (up from -SEK 1.27).

• Equity increased to SEK 102.1 million (from SEK 100.1 million); equity ratio at 40.4% (up from 39.7%).

• Net debt decreased to SEK 28.0 million (from SEK 32.3 million); cash and cash equivalents at SEK 9.7 million (down from SEK 11.9 million).

Outlook and guidance

• Plans to increase marketing investments and expand distribution in North America in H2 2025.

• Focus remains on profitable expansion, product innovation, and strengthening positions in existing markets.

• Management expects continued long-term growth in dietary supplement consumption globally.